tiprankstipranks
Trending News
More News >
Humana Inc (HUM)
NYSE:HUM
Advertisement

Humana (HUM) AI Stock Analysis

Compare
2,536 Followers

Top Page

HUM

Humana

(NYSE:HUM)

Rating:71Outperform
Price Target:
$325.00
▲(4.82% Upside)
Humana's overall stock score reflects strong financial performance and a positive earnings outlook, supported by strategic initiatives like Medicaid expansion and CenterWell Pharmacy's growth. Technical indicators show bullish momentum, though caution is advised due to overbought signals. Valuation is fair, and the new credit agreement enhances financial flexibility. However, challenges in the home health segment and ongoing litigation present risks.
Positive Factors
Earnings
2Q results look good, with adj EPS of $6.27 coming in above consensus by 6%.
Financial Performance
HUM raised its 2025 adjusted EPS guide to approximately $17.
Negative Factors
Legal Issues
Humana lost its Star ratings lawsuit, which could impact financial outcomes.
Regulatory Challenges
An increased amount of the Stars headwind is expected to directly affect pre-tax margin, leading to a decrease in projected earnings per share for 2026.

Humana (HUM) vs. SPDR S&P 500 ETF (SPY)

Humana Business Overview & Revenue Model

Company DescriptionHumana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
How the Company Makes MoneyHumana generates revenue primarily through premium payments received from its members for health insurance coverage. The company's key revenue streams include Medicare Advantage plans, which are funded by the federal government and provide comprehensive health services to eligible seniors. Additionally, Humana earns revenue from its Individual and Family plans, employer-sponsored group health plans, and Medicare prescription drug plans. The company also benefits from partnerships with healthcare providers and organizations, which help improve care management and reduce costs. These partnerships, along with its focus on value-based care, contribute to Humana's ability to optimize health outcomes and enhance its financial performance.

Humana Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Breaks down sales figures for each business unit, indicating which areas are contributing most to growth and where there might be potential for expansion or risk.
Chart InsightsHumana's revenue dynamics reveal a strategic pivot, with the Insurance segment gaining prominence since 2023, offsetting the absence of Retail and Healthcare Services revenue. CenterWell Pharmacy's strong performance, highlighted in the earnings call, aligns with this shift, driving the increased EPS outlook for 2025. Despite challenges like home health rate cuts and litigation, Humana's Medicaid expansion and improved Medicare Advantage membership retention are positive indicators. The company's focus on operational efficiency and clinical excellence supports its long-term growth trajectory, enhancing shareholder value.
Data provided by:Main Street Data

Humana Earnings Call Summary

Earnings Call Date:Jul 30, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
Humana's earnings call presented a generally positive outlook, with raised EPS guidance, strong performance in CenterWell Pharmacy, and progress in Medicaid expansion. However, ongoing litigation related to Stars and challenges in the home health segment present some concerns.
Q2-2025 Updates
Positive Updates
EPS Outlook Raised
Humana raised its full-year 2025 EPS outlook from approximately $16.25 to $17, driven by better-than-expected performance in CenterWell Pharmacy and individual MA membership.
Medicaid Expansion
Humana expanded its Medicaid footprint to 10 states, with 3 more states awarded and pending, indicating strategic growth in this segment.
CenterWell Pharmacy Outperformance
CenterWell Pharmacy saw higher direct-to-consumer volume and favorable drug mix, contributing to better-than-expected performance.
Strong Individual MA Membership
Individual MA membership declined less than expected, with improvements in member retention and bounce-back members who returned to Humana.
Negative Updates
Stars Litigation
Humana's Stars litigation was dismissed on administrative grounds, leading the company to refile the case. This ongoing legal issue presents uncertainty.
Proposed Home Health Rate Reduction
The proposed 6% net rate reduction in home health reimbursement is seen as challenging and not reflective of the current wage and inflation environment.
Company Guidance
During Humana's second quarter earnings call for fiscal year 2025, the company raised its full-year EPS outlook from approximately $16.25 to $17, driven by strong performance in CenterWell Pharmacy and better-than-expected individual Medicare Advantage (MA) membership. Humana's medical cost trends aligned with expectations, while strategic actions in MA products and experiences helped reduce membership decline. The company highlighted improvements in clinical excellence and operational efficiency, with initiatives like a new partnership with Epic to enhance transparency in healthcare costs. Humana also emphasized its Medicaid expansion, now active in 10 states with 3 more pending, and noted a favorable drug mix in Specialty Pharmacy contributing to CenterWell's outperformance. The second quarter's performance supported an improved full-year adjusted EPS outlook of approximately $17, with an additional $100 million in investments to enhance member outcomes and operational excellence.

Humana Financial Statement Overview

Summary
Humana demonstrates strong revenue growth and effective cost management, evidenced by a high gross profit margin. The balance sheet is stable with moderate leverage, but declining ROE suggests challenges in maximizing shareholder returns. Cash flow generation is robust, though the recent decrease in operating cash flow warrants attention.
Income Statement
75
Positive
Humana's income statement shows a consistent revenue growth trend, with a TTM revenue growth rate of 2.37%. The company maintains a strong gross profit margin of 100%, indicating effective cost management. However, the net profit margin is relatively low at 1.28%, suggesting room for improvement in profitability. The EBIT and EBITDA margins are stable, reflecting operational efficiency.
Balance Sheet
70
Positive
The balance sheet reveals a moderate debt-to-equity ratio of 0.69, indicating a balanced approach to leveraging. The return on equity (ROE) is 9.02%, which is decent but shows a decline from previous years. The equity ratio stands at 36.21%, suggesting a solid equity base relative to total assets.
Cash Flow
68
Positive
Cash flow analysis indicates a positive free cash flow growth rate of 2.44% in the TTM period. The operating cash flow to net income ratio is 0.17, and the free cash flow to net income ratio is 0.83, highlighting strong cash generation relative to net income. However, the operating cash flow has decreased compared to previous periods, which could be a concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue123.11B117.76B106.37B92.87B83.06B77.16B
Gross Profit123.11B117.76B106.37B92.87B83.06B77.16B
EBITDA3.78B3.35B4.79B4.81B4.39B5.50B
Net Income1.58B1.21B2.49B2.81B2.93B3.37B
Balance Sheet
Total Assets50.36B46.48B47.06B43.05B44.36B34.97B
Cash, Cash Equivalents and Short-Term Investments21.71B20.43B21.32B5.06B3.39B4.67B
Total Debt12.59B11.72B11.66B11.13B12.49B6.66B
Total Liabilities32.06B30.03B30.75B27.68B28.25B21.24B
Stockholders Equity18.23B16.38B16.26B15.31B16.08B13.73B
Cash Flow
Free Cash Flow2.44B2.39B2.98B3.47B946.00M4.67B
Operating Cash Flow2.93B2.97B3.98B4.59B2.26B5.64B
Investing Cash Flow-875.00M-2.95B-3.49B-1.01B-6.56B-3.06B
Financing Cash Flow-3.52B-2.49B-856.00M-1.91B3.02B-1.96B

Humana Technical Analysis

Technical Analysis Sentiment
Positive
Last Price310.06
Price Trends
50DMA
255.67
Positive
100DMA
251.71
Positive
200DMA
260.56
Positive
Market Momentum
MACD
14.97
Negative
RSI
79.88
Negative
STOCH
86.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HUM, the sentiment is Positive. The current price of 310.06 is above the 20-day moving average (MA) of 284.48, above the 50-day MA of 255.67, and above the 200-day MA of 260.56, indicating a bullish trend. The MACD of 14.97 indicates Negative momentum. The RSI at 79.88 is Negative, neither overbought nor oversold. The STOCH value of 86.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HUM.

Humana Risk Analysis

Humana disclosed 16 risk factors in its most recent earnings report. Humana reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Humana Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$280.64B13.3823.14%2.76%9.98%52.31%
73
Outperform
$71.75B13.5612.48%2.07%10.21%-17.79%
72
Outperform
$80.31B16.4312.31%1.94%20.93%43.98%
71
Outperform
$36.52B23.809.03%1.14%9.88%-7.25%
70
Outperform
$9.80B8.9223.93%16.12%10.99%
63
Neutral
$14.26B7.327.50%12.96%-23.25%
51
Neutral
$7.86B-0.33-41.57%2.23%23.26%-2.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HUM
Humana
311.98
-54.54
-14.88%
CNC
Centene
29.62
-43.64
-59.57%
CI
Cigna
300.72
-60.86
-16.83%
MOH
Molina Healthcare
183.25
-147.99
-44.68%
UNH
UnitedHealth
308.80
-284.18
-47.92%
ELV
Elevance Health
322.33
-216.47
-40.18%

Humana Corporate Events

Financial Disclosures
Humana Reaffirms 2025 Earnings Guidance in September Meeting
Neutral
Aug 29, 2025

In September 2025, Humana Inc.’s senior management will meet with investors and analysts to reaffirm its earnings guidance for the fiscal year ending December 31, 2025. The company projects approximately $13.77 in diluted earnings per share and $17.00 in adjusted earnings per share, consistent with previous guidance. Humana emphasizes the use of adjusted EPS as a comprehensive measure for evaluating its core operating performance, aiding in planning and decision-making.

Business Operations and StrategyFinancial Disclosures
Humana Lowers 2025 GAAP EPS Guidance
Neutral
Jul 30, 2025

Humana Inc. reported its financial results for the second quarter of 2025, highlighting a GAAP earnings per share (EPS) of $4.51 and an adjusted EPS of $6.27. The company has revised its full-year 2025 guidance, lowering GAAP EPS expectations to approximately $13.77 while raising adjusted EPS guidance to approximately $17.00. Humana also increased its revenue guidance to at least $128 billion and adjusted its Medicare Advantage membership projections to a decline of up to 500,000 members, reflecting strategic exits from unprofitable plans. The company continues to expand its CenterWell operations and launched a new Medicaid contract in Virginia, indicating a focus on sustainable growth and value creation.

Business Operations and StrategyFinancial Disclosures
Humana Reaffirms 2025 Earnings Guidance in June Meetings
Neutral
Jun 2, 2025

Humana Inc. announced that its senior management will meet with investors and analysts throughout June 2025 to reaffirm its earnings guidance for the year ending December 31, 2025. The company projects diluted earnings per share of approximately $14.68 and adjusted earnings per share of approximately $16.25, consistent with its previous guidance. Humana will also host an Investor Conference on June 16, 2025, to discuss its strategic direction and financial performance. The use of Adjusted EPS, which differs from GAAP EPS, is intended to provide a more comprehensive view of the company’s core operating performance.

Private Placements and FinancingBusiness Operations and Strategy
Humana Secures $5 Billion Credit Agreement
Positive
May 30, 2025

On May 30, 2025, Humana Inc. entered into a $5.0 billion unsecured revolving credit agreement with several banks, increasing its previous credit commitment from $2.642 billion. This new agreement replaces an expired $2.1 billion credit agreement and includes provisions for interest rates, facility fees, and covenants, allowing for up to $1.0 billion in incremental commitments. As of the agreement date, Humana had no outstanding borrowings and maintained approximately $4.98 billion in borrowing capacity, which could significantly impact its financial flexibility and operational strategy.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2025